Pfizer's Latest Ozempic Competitor Just Flopped (Again). Is the Stock Still a Buy?

Published on 8 Dec 2023 on Motley Fool

On Dec. 1, Pfizer (NYSE: PFE) reported some less-than-great news to investors. In short, its latest...

Read the rest of the article

Start tracking your investments with Statfolio

Ozempic works by mimicking a hormone that regulates blood sugar and suppresses appetite. In...

Quartz 18 Nov 2024

Polen Capital, an investment management company, released its “Polen Global Growth Strategy”...

Insider Monkey · via Yahoo Finance 15 Nov 2024

The stock's average trading price was $1,112.86 during the quarter, with a -30.47% return over th...

GuruFocus.com · via Yahoo Finance 14 Nov 2024

Novo Nordisk A/S (NYSE:NVO), a global healthcare company specializing in diabetes care and obesit...

Investing.com 13 Nov 2024

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Disruptive analytics’ Substack by Ma...

Insider Monkey · via Yahoo Finance 12 Nov 2024

On Monday, JPMorgan maintained a positive outlook on Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO),...

Investing.com 11 Nov 2024

Novo Nordisk (CSE:NOVOb) has been placed on JPMorgan’s Catalyst Watch list, signaling heightened...

Investing.com 11 Nov 2024

Novo Nordisk (CSE:NOVOb) has been placed on JPMorgan’s Catalyst Watch list, signaling heightened...

Investing.com 11 Nov 2024

Earlier, Novo Nordisk A/S (NYSE:NVO) petitioned the FDA to ban compounding pharmacies from produc...

Benzinga · via Yahoo Finance 7 Nov 2024

Danish drugmaker Novo Nordisk's shares hit an over 9-month low on Thursday after surging more tha...

Reuters · via Yahoo Finance 7 Nov 2024